01 Increasing Adoption of Genomic and Biomarker-Based Testing for Personalized Treatment Selection Growing use of genomic sequencing, molecular diagnostics, and biomarker profiling is enabling healthcare providers to identify patient-specific disease characteristics and select therapies more precisely. These technologies are strengthening treatment stratification, particularly in oncology and rare diseases, while expanding the role of diagnostic testing in personalized care pathways. In May 2026, the World Health Assembly endorsed a resolution supporting the integration of genomic, molecular, clinical, and other health data into targeted and personalized healthcare.
02 Growing Integration of Artificial Intelligence and Multi-Omics Data in Personalized Medicine Artificial intelligence is increasingly being combined with genomic, transcriptomic, clinical, imaging, and other patient-level datasets to improve biomarker interpretation and treatment selection. This convergence helps healthcare and research organizations process complex biological information more efficiently, supporting more individualized clinical decision-making and accelerating precision-focused drug development. In June 2026, a peer-reviewed review highlighted the growing role of AI and multi-omics integration in biomarker discovery, patient stratification, therapy selection, and personalized treatment.
01 Increasing Availability of Targeted Therapies and Companion Diagnostics Supports Personalized Medicine Market Growth The expanding development and availability of targeted therapies and companion diagnostic products are strengthening the clinical application of personalized medicine. Pharmaceutical companies are increasingly developing treatments around specific molecular targets, while companion diagnostics help identify appropriate patient populations and support therapy selection. This expansion is increasing the practical use of personalized approaches across oncology and other disease areas.
01 High Costs of Genomic Testing and Advanced Data Infrastructure Can Limit Adoption Personalized medicine often requires specialized sequencing platforms, molecular diagnostics, bioinformatics infrastructure, and skilled professionals to generate and interpret patient-specific data. These requirements increase implementation and testing costs, making advanced personalized healthcare more difficult to deploy in healthcare systems with limited budgets and infrastructure.
01 Expansion of Personalized Medicine Across Rare Diseases and Chronic Conditions Creates New Growth Opportunities . Broader genomic testing and biomarker discovery can support earlier diagnosis, patient stratification, and treatment optimization across diverse disease populations, creating additional opportunities for personalized medicine solutions.
01 Data Integration, Privacy, and Unequal Access Create Challenges for Personalized Medicine Adoption Personalized medicine depends on combining genomic, clinical, and other patient-level information across laboratories, hospitals, research institutions, and digital platforms. Differences in data standards, privacy requirements, infrastructure, and population representation can make information sharing and clinical integration difficult while increasing the risk of unequal access to personalized healthcare.
June 2026 Illumina expanded its precision medicine solutions with advancements in next-generation sequencing platforms and clinical genomics workflows. The company continued supporting personalized treatment decisions through improved genomic profiling technologies.
March 2026 Roche expanded its personalized healthcare portfolio through advancements in companion diagnostics and molecular testing solutions. The initiatives support targeted therapies by enabling biomarker-driven treatment selection.
January 2026 Thermo Fisher Scientific expanded its clinical sequencing and precision medicine offerings with new genomic analysis solutions. The technologies support pharmaceutical research, oncology testing, and personalized treatment development.
October 2025 QIAGEN expanded its precision medicine portfolio with new molecular diagnostic solutions and biomarker testing capabilities. The developments support targeted therapy selection and personalized healthcare applications.